Metastatic Colorectal Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Metastatic Colorectal Cancer Emerging Therapy and TPP Insights

Thelansis’s “Metastatic Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer is the advanced disseminated stage of colorectal cancer, with liver, lung, and peritoneum representing the most frequent metastatic sites, driven by accumulated somatic mutations in APC, KRAS, NRAS, BRAF V600E, and PIK3CA alongside mismatch repair status profoundly influencing therapeutic selection and prognosis. Comprehensive molecular profiling encompassing RAS and BRAF mutation status, mismatch repair and MSI testing, HER2 amplification, and NTRK fusion analysis is mandatory at diagnosis. Patients present with progressive systemic deterioration, weight loss, and symptoms referable to metastatic sites. For RAS and BRAF wild-type left-sided tumours, FOLFOX or FOLFIRI combined with cetuximab or panitumumab constitutes standard first-line therapy; bevacizumab combinations address right-sided and RAS-mutated disease. MSI-H disease benefits profoundly from pembrolizumab as first-line standard. BRAF V600E mutated mCRC is now treated frontline with encorafenib plus cetuximab combined with mFOLFOX6 or FOLFIRI, following BREAKWATER trial FDA approval in early 2026, more than doubling overall survival compared to chemotherapy alone. HER2-amplified RAS wild-type disease responds to tucatinib-trastuzumab combinations. NTRK fusion-positive disease benefits from larotrectinib or entrectinib. Fruquintinib and trifluridine-tipiracil address chemorefractory later-line disease. Surgical resection of oligometastatic disease offers curative intent in selected patients. Multidisciplinary tumour board evaluation, clinical trial participation, and early palliative integration are indispensable to patient-centred care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Metastatic Colorectal Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026